Notable & novel scientific awards to celebrate.
2023: January, February, March, April, May, June, July, August, September, October, November, December
December 2023New Federal Awards: |
|||
| Sanjana Dayal | Internal Medicine | NIH RO1 4 years |
Preventive mechanisms of Age-associated Thrombosis |
| John Fingert, Contact PI Todd Scheetz, MPI Budd Tucker, MPI |
Ophthalmology | NIH R21 2 years |
Stem cell approaches to normal tension glaucoma |
| Robert Piper, Contact PI Chris Anern, MPI |
Physiology | NIH R33 2 years |
Towards systematic analysis of cardiac voltage-gated sodium channel beta subunit Function |
| Eric Taylor | Physiology | NIH R01 4 years |
Regulation of Hepatic Fuel Fluxes by the Mitochondrial Dicarboxylate Carrier |
| Mary Weber | Microbiology | NIH R61 3 years |
Development of genetic tools for overexpression and targeted mutagenesis of Orientia tsutsugamushi TPR proteins |
|
Competitive Awards: |
|||
| Enrique Leira | Neurology | NIH U24 5 years |
The University of Iowa's Regional Stroke Research Network |
|
|||
| Stephanie Chen | Pathology | Exact Sciences Corporation 3 years |
Specimen Collection Study to Evaluate Biomarkers in Subjects with Cancer |
| Nabeel Hamzeh | Internal Medicine | Bristol-Myers Squibb Company 3 years |
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis |
| Markus Kuehn | Ophthamology | Animal Eye Consultants of Iowa 2 years |
Adaptive Immune Responses Contributing to Canine Glaucoma |
| Delwyn Miller | Psychiatry | University of Southern California 5 years |
Alzheimer's Disease Neuroimaging Initiative (ADNI4) |
| Amy Ryan | Anatomy and Cell Biology | Children's Hospital of Los Angeles 1 year |
Development of a model that integrates inflammation and tissue injury to predict and mitigate the post-acute sequelae of COVID-19 |
| Michael willey | Orthopedics | MEND Nutrition, Inc. 3 years |
MENDTM Clinical Trial Proposal |
|
November 2023New Federal Awards: |
|
||
| Yi Huang | Internal Medicine | NIH R01 3 years |
Role of LSD1 in Triple Negative Breast Cancer Development and Therapeutic Response |
|
Competitive Awards: |
|||
| Stanley Perlman | Microbiology | NIH R01 5 years |
Role of LSD1 in Triple Negative Breast Cancer Development and Therapeutic Response |
|
Other Awards: |
|||
| Umar Farooq | Internal Medicine | Cargo Therapeutics 5 years |
An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-Directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants With Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CART-cell |
| Umar Farooq | Internal Medicine | Janssen Research & Development, Inc. 4 years |
A Phase 1b Multicenter, Open-label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non- Hodgkin Lymphoma |
| Philip Gander, Contact PI Joel Berger MPI |
Radiology, Neurosurgery |
REAM Foundation, |
Novel Investigation of Brain Mechanisms for Different Triggers in Misophonia |
| Dilek Ince | Internal Medicine | Corixa Corporation 3 years |
A Phase 2b, randomized, controlled, open-label study to evaluate the immune response and safety of the RSVPreF3 OA investigational vaccine in adults (50 years of age) when administered to lung and renal transplant recipients comparing 1 versus 2 doses an |
| Annie Killoran | Nurology | Genetech, Inc. 3 years |
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study To Evaluate The Safety, Biomarkers, And Efficacy Of Tominersen In Individuals With Prodromal And Early Manifest Huntington's Disease |
| Douglas Laux | Internal Medicine | Replimune, Ltd. 3 years |
A Phase 2, Open-label, Multicenter Study Investigating RP3 in Combination with Other Therapy in Patients with Locoregionally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck |
| Douglas Laux | Internal Medicine | Seagen, Inc. 3 years |
A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors |
| Mohammed Milhem | Internal Medicine | Seagen, Inc. 3 years |
A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors |
| Sneha Phadke | Internal Medicine | AstraZeneca Pharmaceuticals LP 3 years |
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/ |
| Chen Tan | Internal Medicine | Ansun Biopharma, Inc. 3 years |
A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS 181 for the Treatment of Lower Respiratory Tract Parain:fluenza Infection in Immunocompromised Subjects |
| Yousef Zakharia | Internal Medicine | Worldwide Clinical Trials, Inc. 3 years |
A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM -RESISTANT OVARIAN CARCINOMA, ENDOMETRIAL ADENOCARCINOMA, AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS |
|
October 2023New Federal Awards: |
Top of Page | ||
| James Byrne | Radiation Oncology | NIH K08 5 years |
Exploiting Carbon Monoxide Biofoams to Radio-Sensitize Rectal Cancer Cells While Protecting Normal Bowel |
| Grace Ciampa | Internal Medicine | NIH F31 2 years |
Examining the Function of a Novel Protein in the Cardiac Junctional Membrane Complex |
|
Competitive Awards: |
|||
| Thomas Scholz | Pediatrics | Iowa Department of Human Services 1 year |
MHDS 24-008 Community Circle of Care |
| Kirill Nourski | Neurosurgery | University of Wisconsin-Madison 4 years |
Mechanisms of Loss, Recovery and Disorders of Consciousness |
|
Other Awards: |
|||
| Ernesto Ruiz Duque | Internal Medicine | Bristol-Myers Squibb Company 3 years |
DISCOVER-HCM |
| Rami El Abiad | Internal Medicine |
Celldex Therapeutics, Inc. 3 years |
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis |
| Andrew Russo | Molecular Physics & Biophysicis | Seattle Institute for Biomedical and Clinical Research 5 years |
Role of Sleep Disruption after mTBI as a Driver of Chronic Post-Traumatic Headache |
| Alejandro Comellas Freymond | Internal Medicine | IQVIA RDS Inc. 3 years |
A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough, Including Unexplained Chronic Cough (CALM-1) |
| Muhammad Furqan | Internal Medicine | AbbVie, Inc. 3 years |
A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalimab (ABBV-181), carboplatin, or cisplatin in adult subjects with advanced solid tumors. |
| Muhammad Furqan | Internal Medicine | BeiGene USA 3 years |
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors |
| Muhammad Furqan | Internal Medicine | Poseida Therapeutics, Inc. 3 years |
A PHASE 1 DOSE ESCALATION AND EXPANDED COHORT STUDY OF P-MUC1C-ALLO1 IN ADULT SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS |
| David Axelrod | Surgery | CTI Clinical Trial Services, Inc. 3 years |
An open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA 99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase with standa |
| Sneha Phadke | Internal Medicine | NSABP Foundation, Inc. 5 years |
CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or |
| Carla Nester | Pediatrics | Apellis Pharmaceuticals, Inc. 3 years |
AN OPEN-LABEL, NONRANDOMIZED, MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF PEGCETACOPLAN IN PARTICIPANTS WITH C3 GLOMERULOPATHY OR IMMUNE-COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS |
| Patrick Sinn | Pediatrics | Cystic Fibrosis Foundation 2 years |
005661G223 Base-Editing for Life-Long Correction of CF Airways |
| Vishnu Mani | Surgery | Direct Biologics, LLC 3 years |
Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles for Hospitalized Patients with Moderate-to-Severe ARDS: A Phase III Clinical Trial |
| Eric Hoffman | Radiology | Imperial College London 2 years |
THE BLF EARLY COPD DEVELOPMENT PARTNERSHIP GRANT |
| Brian Link | Internal Medicine | Mayo Clinic 3 years |
Characteristics and outcomes of patients with Diffuse Large B-cell Lymphoma Receiving Frontline Treatment at Cancer Centers within the LEO Cohort, ML43785 |
|
September 2023New Federal Awards: |
Top of Page | ||
| John Fingert, Contact PI Todd Scheetz, MPI |
Ophthalmology | NIH R01 5 years |
Genetic Factors for Glaucoma in the OHTS; Risk, Progression and Mechanism |
| Aloysius Klingelhutz | Microbiology | NIH R21 2 years |
The role of ISG15 and ISGylation in the senescence-associated secretory phenotype |
| Elizabeth Newell | Pediatrics | NIH R01 5 years |
Mechanisms of type I interferon neuropathology following traumatic brain injury |
| Jon Houtman | Microbiology | NIH R25 5 years |
R25 YES: Cancer Research Opportunities at Iowa |
|
Competitive Awards: |
|||
| Milan Sonka, Contact PI John Buatti, MPI |
Radiation Oncology | NIH R56 1 year |
Deep LOGISMOS |
| Vincent Magnotta, Contact PI John Wemmie, MPI |
Radiology, Psychiatry |
NIH R01 5 years |
Cerebellar metabolism, neural circuits, and symptoms in bipolar disorder |
|
Other Awards: |
|||
| Umar Farooq | Internal Medicine | Angiocrine Bioscience, Inc. 3 years |
Angiocrine Long Term Follow-Up Umbrella Study |
| Umar Farooq | Internal Medicine | Nektar Therapeutics 3 years |
A PHASE 2/3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NKTR-255 VS PLACEBO FOLLOWING CD19-DIRECTED CAR-T CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA |
| Bruce Gantz | Otolaryngology | Cochlear Americas 3 years |
Preliminary Evaluation of a Dexamethasone Eluting Electrode Array |
| Marlan Hansen | Otolaryngology | Julius Clinical Research B.V. 3 years |
A Natural History Study in Individuals with Otoferlin Gene (OTOF)-Mediated Hearing Loss |
| Annie Killoran | Neurology | Worldwide Clinical Trials, Inc. 3 years |
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson's Disease With a Pathogenic Variant in the Glucocerebrosidase (G |
| Antonio Sanchez | Internal Medicine | Merck Sharp & Dohme LLC 3 years |
A Phase 2b Randomized, Double-Blind Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults with Precirrhotic Nonalcoholic Steatohepatitis |
| Antonio Sanchez | Internal Medicine | PPD Investigator Services, LLC 3 years |
A Phase 3, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Fazirsiran in Participants With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease |
| Christopher Strouse | Internal Medicine | Poseida Therapeutics, Inc. 3 years |
Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects with Relapsed / Refractory Multiple Myeloma (MM) |
August 2023New Federal Award: |
Top of Page | ||
| Alexander Boyden | Pathology | NIH R01 5 years |
Pathogenic B cell:CD4 T cell interactions in a novel B cell-dependent EAE mouse model of multiple sclerosis |
| Sean Fain | Radiology | NIH R01 5 years |
Dynamic Imaging of Lung Ventilation and Perfusion Using CT and MRI |
| Gena Ghearing | Neurology | CDC 5 years |
Expanding epilepsy self-management support in healthcare networks (EXPAND) |
| Aleksander Lenert | Internal Medicine |
NIH K23 |
Investigating Disease Activity, Bone Damage and Interleukin-1 Genes in Adult SAPHO Syndrome and Chronic Nonbacterial Osteomyelitis |
| Yi Luo | Urology | DOD, CDMRP 4 years |
CP220038 - Development of a novel DNA aptamer-based IFN-y targeted therapy for chronic cystitis pain |
| Wendy Maury, Contact PI Noah Butler, MPI |
Microbiology | NIH UH2 2 years |
Defining the effect of Plasmodium infection on Ebola virus vaccine efficacy |
| Ben Miskle | Pharmacy Practice and Science (Award in Psychiatry) | SAMHSA H79 5 years |
Iowa Naloxone Expansion and Training (IA-NEXT) |
| Catherina Pinnaro | Pediatrics | NIH K23 3 years |
Hyperglycemia in Turner syndrome: Mechanisms and X chromosome contributions |
| Matthew Potthoff | Neuroscience & Pharmacology | NIH R01 5 years |
Therapeutic Potential of FGF21 for Alzheimer's Disease |
| Brett Faine, Contact PI David Talan, MPI |
Emergency Medicine | NIH R21 2 years |
Personalized Antibiotic Therapy in the Emergency Department: PANTHER Trial |
| Seth Tomchik | Neuroscience & Pharmacology | NIH R01 2 years |
Dopaminergic circuit modulation of learning and arousal-mediated memory enhancement |
| Elliott Sohn, Contact PI Jon Houtman, MPI Milan Sonka, MPI |
Ophthalmology, Microbiology, Electrical & Computer Engineering |
NIH R01 4 years |
MMP-9 based immune-driven mechanisms of neovascular AMD |
|
Competitive Awards: |
|||
| Marlan Hansen, Contact PI C. Guymon, MPI |
Otolaryngology | NIH R01 5 years |
Reduction of Intracochlear Trauma and Fibrosis Using Dual Network, Zwitterionic Hydrogel Thin Films on Cochlear Implant Surfaces |
| Robert Mullins, Contact PI Budd Tucker, MPI |
Ophthlamology | NIH R01 4 years |
Choriocapillaris Protection and Replacement in AMD |
|
Other Awards: |
|||
| David Bender | OBGyn | GOG Foundation 3 years |
Randomized, multicenter, open-label, phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FR-positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, |
| James Byrne | Radiation Oncology | V Foundation for Cancer Research 3 years |
Overcoming immunotherapy resistance using oxygen-entrapping materials |
| Marcelo Correia | Internal Medicine | Lilly USA, LLC 3 years |
A Phase 3, Open-Label Study of Once Daily LY3502970 Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4) |
| Umar Farooq | Internal Medicine | ImmPACT Bio USA Inc. 3 years |
A PHASE 1/2 MULTI-CENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF IMPT-314, A CD19/20 BISPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY IN PARTICIPANTS WITH RELAPSED OR REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA |
| Muhammad Furqan | Internal Medicine | AGRESSIVE B-CELL NON HODGKIN LYMPHOMA 3 years |
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy (DeLLphi-304) |
| Muhammad Furqan | Internal Medicine | Elicio Therapeutics, Inc. 3 years |
First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS viral oncogene homolog (NRAS) Mutated Solid Tumors |
| Hillel Haim | Microbiology | ViiV Healthcare 5 years |
Computational platform to personalize Fostemsavir treatment to people living with HIV-1 |
| Asad Javed | Internal Medicine | Lyell Immunopharma, Inc. 3 years |
A Phase 1 Study to Assess the Safety and Efficacy of LYL845 in Adults with Relapsed and/or Refractory Metastatic or Locally Advanced Melanoma and Selected Solid Tumor Malignancies |
| Mohammed Milhem | Internal Medicine | Merck Sharp & Dohme LLC 8 years |
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE- 010) |
| Sneha Phadke | Internal Medicine | Arvinas Estrogen Receptor Inc. 3 years |
An Open-Label, Randomized, Non-Comparative Phase 2 Study of ARV-471 or Anastrozole in Post-Menopausal Women With ER+/HER2- Breast Cancer in the Neoadjuvant Setting |
| Philip Polgreen | Internal Medicine | Pfizer, Inc 4 months |
Developing approaches to estimate a more accurate measure of the burden of influenza |
| Ernesto Ruiz Duque | Internal Medicine | Bristol-Myers Squibb Company 3 years |
ODYSSEY-HCM |
| Lucy Wibbenmeyer | Surgery | PolyNovo Biomaterials Pty Ltd. 3 years |
Pivotal Study to Assess the Safety and Effectiveness of NovoSorb Biodegradable Temporizing Matrix (BTM) in the Treatment of Severe Burn Skin Injuries |
July 2023New Federal Awards: |
Top of Page | ||
| Alexandra Bova | Neurology | NIH F32 1 year |
Nigrostriatal dopamine mechanisms of cognitive control |
| Martine Dunnwald | Anatomy & Cell Biology | NIH R03 1 year |
Popliteal Pterygium syndrome, IRf6, and the periderm |
| Adam Dupuy | Anatomy & Cell Biology | US DoD, CDMRP HT9425-23-1-0780 3 years |
ME220036 Identification of genetic mechanisms driving transition of benign nevi to malignant melanoma |
| Oliver Gramlich | Ophthlamology | NIH R03 5 years |
Targeting Cholesterol Homeostasis to maintain vision in MS-like optic neuritis |
| Xiaoyang Hua | Otolaryngology | NIH R01 5 years |
The nose-lung cross talk in upper respiratory virus infection induced asthma exacerbations |
| Miles Pufall | Biochemistry & Molecular Biology | US National Science Foundation 2324615 3 years |
NSF/MCB-BSF: The effect of transcription factor binding on UV lesion accumulations |
| Chen Tan | Internal Medicine | NIH R01 2 years |
NK cell responses to JC polyomavirus |
| Tomohiro Tanaka | Internal Medicine | US DoD, CDMRP k08 5 years |
Estimating the Causal Effect of Liver Allocation Policy Reflecting the Heterogeneity from Age and Geography |
| Kristina Thiel | OBGyn | US DoD, CDMRP HT9425-23-1-0744 4 years |
CA220729P1 - Progestin therapy for endometrial cancer |
|
Other Awards: |
|||
| Loreen Herwaldt | Internal Medicine | University of Wisconsin-Madison 2 years |
Povidone-iodine to Stop Access-Related Infections and Transmission of Staphylococcus Aureus (PAINTS) |
| Katie Larson Ode | Pediatrics | Worldwide Clinical Trials, Inc. 3 years |
A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Setmelanotide in Patients with Acquired Hypothalamic Obesity |
| Kelly Mulfaul | Ophthalmology |
BrightFocus Foundation |
Investigating Human Choroidal Macrophage Recruitment and Activation in Age-related Macular Degeneration - Mulfaul 2022 - BrightFocus |
| Sneha Phadke | Internal Medicine | Olema Pharmaceuticals, Inc. 3 years |
A Phase 1b Open-Label Multicenter Study of OP-1250 in Combination with the CDK4/6 Inhibitor Ribociclib or with the PI3K Inhibitor Alpelisib in Adult Subjects with Advanced and/or Metastatic HR Positive, HER2 Negative Breast Cancer |
| Donna Santillan, Contact PI Mark santillan, MPI |
OBGyn | Heartland Health Research Alliance, LTD 3 years |
Heartland |
| Tomohiro Tanaka | Internal Medicine | PPD Investigator Services, LLC 3 years |
Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in HBeAg-negative Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B Virus (B-Well 1) |
| George Weiner | Internal Medicine | V Foundation for Cancer Research 4 years |
T cell help and resistance to anti-cancer monoclonal antibody therapy |
| Yousef Zakharia | Internal Medicine | Astellas Pharma Global Development, Inc. 3 years |
A Phase 1 Study of ASP1002 in Participants with Metastatic or Locally Advanced Solid Tumors |
| Yousef Zakharia | Internal Medicine | AstraZeneca LP 3 years |
A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients I |
|
June 2023New Federal Awards: |
Top of Page | ||
| Marina Del Rios | Emergency Medicine | NIH R01 4 years |
Dime la VerDAD - Verify, Debunk, and Disseminate |
| Joel Geerling | Neurology | NIH R01 5 years |
Brainstem cold-defense circuitry |
| Corinne Griguer | Radiation Oncology | NIH R01 5 years |
Mitochondria electron transport chain complexes adaptative responses to cellular stress |
| John Harty | Pathology | NIH R21 2 years |
Regulating Pathogen-induced Protective and Pathogenic CD8 T cells in the CNS |
| Diana Jalal, Contact PI Richard Smith, MPI |
Internal Medicine, Otolaryngology |
NIH R01 5 years |
The Alternative Pathway of Complement: A Potential Contributor to Adverse Outcomes in CKD |
| Benjamin Kelvington | Neuroscience & Pharmacology | NIH F31 3 years |
Defining the molecular impact of 16p11.2 deletion on reward response in striatal dopamine receptor D1-expressing neurons |
| Scott Lieberman | Pediatrics | NIH R01 5 years |
Tyk2 and Associated Cytokines in Salivary Gland Autoimmunity |
| Allison Momany | Pediatrics | NIH K99 2 years |
Neonatal Stress in Very Preterm Infants: Longitudinal Effects on Epigenetics and Neurodevelopment |
| Andrew Sullivan | Neuroscience & Pharmacology | NIH F31 3 years |
The Role of IRX3 Neurons in the Regulation of Body Weight Homeostasis |
Other Awards: |
|||
| Ted Abel | Neuroscience & Pharmacology | George Mason University 5 years |
Estradiol signaling pathways mediating sex differences in striatal synaptic plasticity |
| Sabarish Ayyappan | Internal Medicine | Mayo Clinic 3 years |
Randomized phase 2 study with safety run-in of PD-1 inhibitor and IgG4 SIRP-Fc fusion protein (TTI-622) and PD-1 inhibitor and IgG1 SIRP-Fc fusion protein (TTI-621) in relapsed Diffuse Large B-Cell Lymphoma (DLBCL) |
| Chandrikha Chandrasekharan | Internal Medicine | Astellas Pharma, Inc 3 years |
A Phase 1/1b study of ASP2074 in participants with Metastatic or Locally Advanced solid tumors |
| Rami El Abiad | Internal Medicine | Ellodi Pharmaceuticals, L.P. 3 years |
Fluticasone propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Randomized, Double-blind, Placebo-Controlled 24-Week Induction Study of APT-1011, followed by a Single-arm Open-label Extension, in Adult Subjects with Eosinophilic |
| Muhammad Furqan | Internal Medicine | Tempus Labs, Inc. 3 years |
TEMPUS GEMINI NSCLC SURVEILLANCE STUDY |
| Jeremy Greenlee | Neurosurgery | Massachusetts Eye & Ear Infirmary | Next-generation clinical phenotyping and pathophysiology of laryngeal dystonia and voice tremor, Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor (Project 3) |
| Serena Gumusoglu | OBGyn | Burroughs Wellcome Fund 4 years |
Next Gen Pregnancy Initiative |
| Patrick McGonagill | Surgery | CSL Behring LLC 3 years |
CSL Behring TAP Study |
| Jacob Michaelson | Psychiatry | Columbia University 1 year |
Triangulation of missense variant impact through multimodal modeling and functional assays |
| Sneha Phadke | Internal Medicine | PSI Pharma Support America, Inc. 3 years |
An Open-label Multicenter Phase 1b-2 Study of Elacestrant as Monotherapy and in Combination with Abemaciclib in Women and Men with Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer (ELECTRA) |
| Andrea Swenson | Neurology | Massachusetts General Hospital 2 years |
An Expanded Access Protocol of Intravenous Trehalose Injection 90 mg/mL Treatment of Patients with Amyotrophic Lateral Sclerosis |
| Richard Tyler | Otolaryngology | Sage Therapeutics, Inc. 3 years |
AN OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF BREXANOLONE IN THE TREATMENT OF ADULT PARTICIPANTS WITH TINNITUS |
|
May 2023New Federal Awards: |
Top of Page | ||
| Bryan Allan, Contact PI John Buatti, MPI |
Radiation Oncology | NIH R21 2 years |
Redox manipulation of iron to improve glioblastoma therapy: A phase 1 trial |
| Polly Ferguson, Contact PI Alaxander Bassuk, MPI |
Pediatrics | NIH K12 5 years |
CTSA K12 PROGRAM AT THE UNIVERSITY OF IOWA |
| Donna Santillan | ObGyn | NIH R25 5 years |
Beginning and Early Stage Translational (BEST) Researchers |
| Seth Tomchik | Neuroscience & Pharmacology | NIH R01 1 year |
Mechanisms of Nf1 Pathophysiology Underlying Hyperactivity |
| Ergun Uc, Contact PI Nandakumar Narayanan, MPI Soura Dasgupta, MPI |
Neurology, Electrical & Computer Engineering |
NIH RF1 |
Linear predictive coding of EEG Activity for Diagnosis of Parkinson's Disease (LEAD-PD) |
Competitive Awards: |
|||
| Bruce Gantz | Otolaryngology | NIH P50 5 years |
Iowa Cochlear Implant Clinical Research Center VIII |
Other Awards: |
|||
| Chandrikha Chandrasekharan | Internal Medicine | Pharmaceutical Research Associates 3 years |
A randomised, open-label, Phase II, dose/schedule optimisation study of NUC-3373/leucovorin/irinotecan plus bevacizumab (NUFIRI-bev) versus 5-FU/leucovorin/irinotecan plus bevacizumab (FOLFIRI-bev) for the treatment of patients with previously treated... |
| Alicia Gerke | Internal Medicine | Merck Sharp & Doheme LLC 3 years |
INSIGNIA-COPD |
| Marlan Hansen | Otolaryngology | Akouos, Inc 3 years |
A Phase 1/2 Trial of AAVAnc80-hOTOF Gene Therapy in Individuals with Sensorineural Hearing Loss due to Biallelic Otoferlin Gene (OTOF) Mutations |
| Tahaunty Pena | Internal Medicine | Renovion, Inc. 3 years |
A Phase 3 Open-Label, Randomized, Standard of Care-controlled Parallel Arm Study to Demonstrate Efficacy and Safety of ARINA-1 in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) Progression in Participants with Bilateral Lung Tr |
| Andrea Swenson | Neurology | Massachusetts General Hospital 3 years |
HEALEY ALS Platform Trial, Task 12 |
| Michael Tomasson | Internal Medicine | Pfizer, Inc. 3 years |
A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA |
| Douglas Van Daele | Otolaryngology | Nyxoah SA 3 years |
ACCCESS Study - A multicenter study to assess the safety and effectiveness of the Genio dual-sided hypoglossal nerve stimulation system for the treatment of obstructive sleep apnea in subjects with complete concentric collapse of the soft palate. |
| Patricia Winokur | Internal Medicine | Pfizer, Inc 3 years |
A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE |
|
April 2023New Federal Awards: |
Top of Page | ||
| Mahmoud Abou Alaiwa | Internal Medicine | NIH R01 5 years |
Contribution of Small Airways to Mucociliary Transport Dysfunction |
| Hillel Haim | Microbiology | NIH R01 4 years |
Predicting HIV-1 escape from therapeutics in vitro and in vivo - toward personalizing medicine for people living with HIV |
| Vincent Magnotta | Radiology | NIH S10 1 year |
University of Iowa - 7T Small Animal MRI Upgrade |
| Robert Roghair | Pediatrics | NIH R01 5 years |
Sedentary behavior, physical activity, and 24-hour behavior in pregnancy and offspring health: the Pregnancy 24/7 Offspring Study |
| Robert Roghair | Pediatrics | NIH T35 5 years |
Iowa Medical Student Summer Research Program in trans-NIDDK Research |
| Seth Tomchik | Neuroscience & Pharmacology | NIH R01 4 years |
Genetic and molecular mechanisms of Nf1-dependent neuronal regulation of metabolism |
| Aislinn Williams | Psychiatry | Dod, CDMRP 3 years |
AR220030_Validating tRNA viruses to target SCN2A-related autism phenotypes |
Competitive Awards: |
|||
| Tarah Colaizy | Pediatrics | NIH UG1 7 years |
NICHD Cooperative Multicenter Neonatal Research Network |
| Peggy Nopoulos, Contact PI John Wemmie, MPI |
Psychiatry | NIH T32 5 years |
The Iowa Neuroscience Specialty Program in Research Education (INSPIRE) |
| Patrick Sinn | Pediatrics | NIH R01 4 years |
Life-long phenotypic correction of CF airways |
Other Awards: |
|||
| Sabarish Ayyappan | Internal Medicine | Kite Pharma, Inc. 5 years |
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) |
| Chandrikha Chandrasekharan | Internal Medicine | Pfizer, Inc. 3 years |
A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EVIDENCE OF ANTI-TUMOR ACTIVITY OF PF-07284892 (ARRY-558) AS A SINGLE |
| Umar Farooq | Internal Medicine | Kure.ai 3 years |
CASE2422 A phase 1 single arm, open label study to evaluate the safety of UF-KURE19 cells in patients with relapsed or refractory B cell non-Hodgkin lymphomas. |
| Muhammad Furqan | Internal Medicine | AstraZeneca Pharmaceuticals LP 3 years |
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line |
| Steven Lentz | Internal Medicine | Novo Nordisk, Inc 3 years |
Frontier 4 |
| Steven Lentz | Internal Medicine | Novartis Pharmaceuticals Corporation 3 years |
A PHASE 1B, OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ALPN-303 IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4) |
| Janet Pollard | Radiology | Novartis Pharmaceuticals Corporation 3 years |
PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate |
| Erin Shriver | Opthalmology | Viridian Therapeutics, Inc 3 years |
A Multiple Ascending Dose (MAD) Safety, Tolerability and Efficacy Study of VRDN-001, A Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Normal Healthy Volunteers (NHVs) and Subjects With Thyroid Eye Disease (TED) |
|
March 2023New Federal Awards: |
Top of Page | ||
| Zuhair Ballas | Internal Medicine | NIH S10 1 year |
Full Spectrum Cell Sorter Flow Cytometer |
| Maya Evans | Psychiatry | NIH F21 1 year |
Cellular and molecular investigations of striatal enlargement in prenatal stress model of neurodevelopmental risk |
| Marlan Hansen, Contact PI Patricia Winokur, MPI |
Otolarygology, Internal Medicine |
NIH UM1 7 years |
University of Iowa Institute for Clinical and Translational Science |
| Robert Roghair | Pediatrics | NIH T35 5 years |
Medical Student Summer Research Program |
| Maria Spies, Contact PI Michael Spies, MPI |
Biochemistry & Molecular Biology, PSET |
NIH R21 2 years |
Natural products inhibitors targeting homology-directed DNA repair for cancer therapy |
| Stefan Strack | Neuroscience, Pharmacology |
NIH R21 2 years |
Interplay between tau and PKA condensates in ADRD |
| Seth Tomchik | NIH R01 5 years |
Mechanisms of compartmentalized plasticity in learning and memory | |
Competitive Awards: |
|||
| David Gordon | Pediatrics | NIH R37 2 years |
Gene expression signature based screening in Ewing sarcoma |
| Jia Luo | Pathology | NIH R01 5 years |
Endoplasmic Reticulum Stress and Alcohol neurotoxicity |
| David Weiss, Contact PI Regina McGrane, MPI |
Mirobiology | NSF 3 years |
REU Site: Microbiology at the host-pathogen interface |
Other Awards: |
|||
| John Bernat | Pediatrics | Sanofi US Services, Inc 3 years |
A Phase 3, Multicenter, Multinational, Randomized, Double-Blind, Double-Dummy, Active-Comparator Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients with Gaucher Disease Type 3 (GD3) Who have Reached Therapeutic Goals w |
| Muhammad Furqan | Internal Medicine | Immunocore Limited 3 years |
A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers |
| Katherine Mathews | Pediatrics | Virginia Commonwealth University 3 years |
GRASP-01-002- Defining Clinical Endpoints in Becker Muscular Dystrophy |
| Praveen Vikas | Internal Medicine | Pharmaceutical Research Associates 3 years |
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in |
| Daniel Berg | Internal Medicine | Astellas Pharma Global Development, Inc 3 years |
A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Panc |
| Tomohiro Tanaka | Internal Medicine | PPD Investigator Services, LLC 3 years |
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis |
| Alejandro Comellas Freymond | Internal Medicine | AstraZenica AB 3 years |
A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). |
| Antonio Sanchez | Internal Medicine | Zydus Therapeutics Inc 3 years |
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium in Subjects with Primary Biliary Cholangitis |
| Andrea Swenson | Neurology | Massachusetts General Hospital 3 years |
HEALEY ALS Platform Trial, Task # 11 |
| Steven Polyak | Internal Medicine | TriNetX 2 years |
A Retrospective Observational Study of the Standard of Care, and Medical and Surgical Treatment Patterns in Crohn's Perianal Fistulas (CPF) in the U.S. |
|
February 2023New Federal Awards: |
Top of Page | ||
| Ernesto Fuentes | Biochemistry | NIH R01 5 years |
Molecular Mechanisms Regulating Bacterial Two-component Signaling Systems |
| Kristin Claflin | Neuroscience & Pharmacology | NIH K01 5 years |
Regulation of neuronal function by mitochondrial uncoupling |
| Georgina Aldridge | Neurology | NIH R01 5 years |
Cortical Alpha-Synuclein in Dementia |
| Markus Kuehn | Ophthalmology | NIH R01 4 years |
T-cell mediated RGC damage in glaucoma |
| Damian Krysan | Pediatrics | NIH R21 2 years |
Systematic Genetic Analysis of C. albicans CNS Infection |
Competitive Awards |
|||
| Noah Butler | Microbiology | NIH R01 5 years |
Development and function of CD4+ memory T cells during malaria |
| Noah Butler | Microbiology | NIH R01 5 years |
Regulation of Plasmodium-specific CD4+ T cells |
| Richard Smith - Contact PI Carla Nester - MPI Patrick Breheny - MPI |
Otolaryngology, Pediatrics, and Biostatistics |
NIH R01 5 years |
C3 Glomerulopathy - A Collaborative Study |
| Alexander Bassuk | Pediatrics | NIH K12 5 years |
Molecular and Cellular Research to Advance Child Health |
Other Awards |
|||
| Ferhaan Ahmad | Internal Medicine | Cytokinetics, Inc 3 years |
SEQUOIA-HCM OLE |
| Stephan Arndt | Psychiatry | Northeast Iowa Behavioral Health 4 years |
Evaluation project: Certified Community Behavioral Health Clinic Planning, Development, and Implementation Grant (CCBHC) |
| John Bernat | Pediatrics | AVROBIO, Inc 3 years |
A Follow-Up Study of Subjects with Type 1 Gaucher Disease Who Previously Received AVR-RD-02 |
| Linda Cadaret | Internal Medicine | Acceleron Pharma, Inc 3 years |
SOTERIA: An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH |
| Chandrikha Chandrasekharan | Internal Medince | CG Pharmaceuticals, Inc 3 years |
A Phase 1b/2, Dose-escalation, Randomized, Multicenter Study of Maintenance Ivaltinostat plus Capecitabine or Capecitabine Monotherapy in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on First Line FOLFIRINOX Chemoth |
| Rami El Abiad | Internal Medince | AstraZenica Pharmaceuticals LP 3 years |
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis |
| Umar Farooq | Internal Medince | PRA Health Sciences 3 years |
Long-term Follow-up Protocol for Subjects Treated with Adicet Allogeneic Gamma Delta () CAR T Cell Investigational Products |
| Asad Javed | Internal Medince | Replimune, Inc 3 years |
An Open-Label, Multicenter, Phase 1 Study of RP3 as a Single Agent and in Combination with PD-1 Blockade in Patients with Solid Tumors |
| Douglas Laux | Internal Medince | Incyte Biosciences Internal S.a.r.l. 3 years |
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS 1) Recurrent/Metastatic Squamous Cell Carci |
| Margarida Magalhaes-Silverman | Internal Medince | Equillium, Inc. 3 years |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease |
| Varun Monga | Internal Medince | Medpace Clinical Research, LLC 3 years |
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma |
| Lama Noureddine | Internal Medince | Otsuka Pharmaceutical Development & Commercialization, Inc. 3 years |
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy Trial of Sibeprenlimab in the Treatment of Immunogl |
| Stefan Strack, Contact PI Marie Gaine, MPI |
Neuroscience & Pharmacology | Eagles Autism Foundation 2 years |
Primary PKA Dysregulation in Marbach-Schaaf Neurodevelopmental Syndrome |
| Patricia Winokur | Internal Medince | Pfizer, Inc. 3 years |
A PHASE 1/2 RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS |
|
January 2023New Federal Awards: |
Top of Page | ||
| Bao Vu | Molecular Physiology & Biophysics | NIH R21 2 Years |
Functional and transcriptome analyses of protein kinases in Candida glabrata antifungal drug resistance |
| Brandon Davies | Biochemistry & Molecular Biology | NIH R01 5 Years |
Regulation of Endothelial Lipase and HDL Metabolism by ANGPTL3 |
| Chris Ahern, Contact PI Barry London, MPI |
Molecular Physiology & Biophysics | NIH R01 4 Years |
A Versatile Chemical-Genetic Approach to Determine Bases for Arrhythmogenesis and Sodium Channelopathies |
| Chris Ahern | Molecular Physiology & Biophysics | NIH R35 5 Years |
Chemical Biology of Voltage-Gated Cation Channels |
| David Stoltz | Internal Medicine | NIH T32 5 Years |
Climate Change and Lung Health Training Program |
| Enrique Leira, Contact PI Anil Chauhan, MPI |
Neurology & Internal Medicine | NIH U01 3 Years |
The University of Iowa Stroke Preclinical Assessment Network to Support Translational Studies for Acute Cerebroprotection |
| Kevin Legge | Pathology | NIH R01 5 Years |
Protection and Immunity after Polyanhydride Nanoparticle Vaccination against Avian Influenza A Virus |
| M Washington | Biochemistry & Molecular Biology | NIH R35 5 Years |
Structural and mechanistic studies of DNA bypass pathways in eukaryotes |
| Nikolai Artemyev | Molecular Physiology & Biophysics | NIH R01 4 Years |
Molecular underpinnings of photoreceptor transcriptional regulation by CRX and NRL |
| Santiago Ortega Gutierrez | Neurology | NIH R03 2 Years |
Novel risk stratification score for patients with acute Cerebral Venous Thrombosis |
Other Awards: |
|||
| Brian Link | Internal Medicine | Mayo Clinic (Prime: Genetech) 3 Years |
Characteristics and Outcomes of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) at Least Two Prior Lines of Systemic Therapy and Treated at Cancer Centers Within the LEO Cohort |
| Chandrikha Chandrasekharan | Internal Medicine | Pfitzer, Inc 3 Years |
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY OF PF-07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07265028 IN PARTICIPANTS |
| Christopher Strouse | Internal Medicine | ICON Clinical Research, LLC (Prime: Takeda) 3 Years |
A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of Intravenous Modakafusp Alfa as Part of Combination Therapy in Adult Patients with Multiple Myeloma |
| Douglas Hornick | Internal Medicine | AN2 Therapeutics 3 Years |
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disease |
| Frank Faraci | Internal Medicine | LeDucq Foundation 5 Years |
Brain Endothelium: A Nexus for Cerebral Small Vessel Disease |
| Grerk Sutamtewagul | Internal Medicine | Pharmaceutical Research Associates (Prime: Gilead Sciences) 3 Years |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia |
| Jon Houtman | Cancer Center | American Cancer Society 3 Years |
Iowa Cancer Research Experience (ICARE) |
| Katherine Mathews | Pediatrics | Asklepios BioPharmaceutical, Inc. 3 Years |
A two-part multicenter study: a randomized, double-blind, placebo-controlled dose-escalation safety and bioavailability phase (Part 1) followed by double-blind, placebo-controlled, adaptive phase (Part 2) study to evaluate the safety and efficacy of LION- |
| Katherine Mathews | Pediatrics | Lexeo Theraputics 6 Years |
A Phase 1/2 Study of the Safety and Efficacy of LX-2006 Gene Therapy in Friedreich's Ataxia |
| Michael Ohl | Internal Medicine | Iowa Department of Public Health (Prime: SAMHSA) 1 Year |
The Integrated Addiction Care Coordination and Essential Support Services (iACCESS) |
| Muhammad Furqan | Internal Medicine | Amgen, Inc. 3 Years |
A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment |
| Rami El Abiad | Internal Medicine | Celgene International II SARL LC 3 Years |
A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS |
| Saima Sharif | Internal Medicine | GlaxoSmithKline LLC 9 Years |
Phase II, Single Arm Study of Neoadjuvant Dostarlimab (TSR-042) in Stage II and III Deficient Mismatch Repair Colon Cancers |
| Seth Tomchik | Neurosciences & Pharmacology | Texas A&M University (Prime: NIH) 2 Years |
The role of Nf1 in sleep-dependent regulation of metabolic function |
| Umar Farooq | Internal Medicine | Caribou Biosciences, Inc. 3 Years |
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) |
| Varun Monga | Internal Medicine | C4 Therapeutics, Inc. 3 Years |
Phase1/2 open-label multicenter study to characterize the safety and tolerability of CFT8634 in subjects with locally Advanced or Metastatic SMARCB1 perturbed cancers Including Synovial Sarcoma and SMARCB1-Deleted Solid Tumors |
| Xingshen Sun | Anatomy & Cell Biology | Cystic Fibrosis Foundation 3 Years |
004590G222 Early life impact of CFTR modulators on the endocrine pancreas and diabetes in CF |
| Top of Page |
Visit the Archives Page for previous awards.